If he is not vaccinated against Covid-19, Novak Djokovic seems to hope that a treatment will be found for the disease. The Serb, whose attempt to participate in the Australian Open has recently caused controversy, has become the majority shareholder of a biotech seeking to fulfill this objective.
Without specifying the amount of his investment, the CEO of QuantBioRes, Ivan Loncarevic, has indeed indicated that Novak Djokovic is “one of the founders” of this Danish company, “created in June 2020”.
The Covid “as a showcase”
He specifies that the objective of this biotech is “to develop a new technology to combat viruses and resistant bacteria”. In the midst of a pandemic, QuantBioRes “decided to use the Covid as a showcase”. “If we succeed with Covid-19, we will succeed with all the other viruses”, estimates Ivan Loncarevic.
Novak Djokovic and his wife Jelena now own 80% of this company, which employs around twenty people, in Denmark but also in Slovenia, the United Kingdom and Australia.
According to Ivan Loncarevic, QuantBioRes is due to begin clinical trials this summer in the UK. The company’s research is based in particular on a peptide (a short chain of amino acids, editor’s note), supposed to prevent SARS-CoV-2 from infecting human cells.